Reports · Flagship
Healthcare Marketing and Compliance Report
Every quarter, Authoritize measures two forces that now move together for regulated healthcare practices: how aggressively the FDA and FTC are enforcing marketing rules, and how patients actually find care through Google and AI assistants. This hub is the flagship read across all of it, and it always points to the most recent edition.
Each edition draws on the Authoritize Atlas, our corpus of FDA warning letters and FTC actions, together with live search-demand and AI-citation measurement across the verticals we serve. The through-line rarely changes. National brands capture the broad, high-volume searches and the AI answers, while local and specific intent stays open to the clinics willing to earn it with accurate, physician-reviewed content.
Latest edition · Q2 2026
The State of Healthcare Marketing and Compliance: Q2 2026
Read the Q2 2026 edition →Other reports
GLP-1 and Weight Loss Marketing Report
The gold rush and the crackdown. Where GLP-1 and weight-loss demand is going, how enforcement is tightening, and which brands own the AI answers.
TRT and Hormone Marketing Report
Hormone optimization sits next to a grey market of SARMs and compounded products. Where demand is, where the enforcement edge is, and who wins AI answers.
Medical Spa and Aesthetics Marketing Report
The most local game in aesthetics. Where med-spa demand concentrates, how product-linked claims draw letters, and how much local ground is still open.
Peptide Marketing Report
The sharpest enforcement edge in the field. Peptides live in an FDA grey zone of 503A and 503B compounding and research-use-only marketing.
Every edition is drawn from the Authoritize Atlas, our corpus of FDA and FTC actions, and from live search and AI-citation measurement. Screen your own marketing against the same rules with the free Claim Checker.